Related Experiment Video
Updated: Jul 30, 2025
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
A cyanine-based NIR fluorescent Vemurafenib analog to probe BRAFV600E in cancer cells
Elisabetta Barresi1, Caterina Baldanzi2, Marta Roncetti3
1Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy; Center for Instrument Sharing of the University of Pisa (CISUP), University of Pisa, Lungarno Pacinotti 43/44, 56126, Pisa, Italy.
Abstract:
BRAF represents one of the most frequently mutated protein kinase genes and BRAFV600E mutation may be found in many types of cancer, including hairy cell leukemia (HCL), anaplastic thyroid cancer (ATC), colorectal cancer and melanoma. Herein, a fluorescent probe, based on the structure of the highly specific BRAFV600E inhibitor Vemurafenib (Vem, 1) and featuring the NIR fluorophore cyanine-5 (Cy5), was straightforwardly synthesized and characterized (Vem-L-Cy5, 3), showing promising spectroscopic properties. Biological validation in BRAFV600E-mutated cancer cells evidenced the ability of 3 to penetrate inside the cells, specifically binding to its elective target BRAFV600E with high affinity, and inhibiting MEK phosphorylation and cell growth with a potency comparable to that of native Vem 1. Taken together, these data highlight Vem-L-Cy5 3 as a useful tool to probe BRAFV600E mutation in cancer cells, and suitable to acquire precious insights for future developments of more informed BRAF inhibitors-centered therapeutic strategies.
Insights
A new fluorescent probe, Vem-L-Cy5, specifically targets and inhibits the BRAFV600E mutation in cancer cells. This probe offers a promising tool for cancer research and the development of targeted BRAF inhibitor therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Chemical Biology
Background:
- The BRAF gene is frequently mutated in various cancers, with the BRAFV600E mutation being a key driver in diseases like melanoma and thyroid cancer.
- Targeting the BRAFV600E mutation is a validated therapeutic strategy, exemplified by the drug Vemurafenib.
Purpose of the Study:
- To synthesize and characterize a novel fluorescent probe, Vem-L-Cy5, for detecting and studying the BRAFV600E mutation.
- To evaluate the probe's ability to bind specifically to BRAFV600E, inhibit downstream signaling, and impact cancer cell growth.
Main Methods:
- Synthesis and characterization of the Vem-L-Cy5 fluorescent probe.
- Biological validation in BRAFV600E-mutated cancer cells.
- Assessment of cellular uptake, target binding affinity, and inhibition of MEK phosphorylation.
Main Results:
- Vem-L-Cy5 was successfully synthesized and demonstrated favorable spectroscopic properties.
- The probe effectively penetrated cancer cells and exhibited high-affinity binding to BRAFV600E.
- Vem-L-Cy5 inhibited MEK phosphorylation and cancer cell growth with potency comparable to Vemurafenib.
Conclusions:
- Vem-L-Cy5 is a valuable tool for probing BRAFV600E mutations in cancer cells.
- The probe provides insights for developing improved BRAF inhibitor-centered therapeutic strategies.
